Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences in June.

Jefferies Healthcare Conference Date: Friday, June 9, 2023Time: 12:15 PM ETLocation: New York, NY

Goldman Sachs 44th Annual Global Healthcare ConferenceDate: Wednesday, June 14, 2023Time: 9:20 AM PTLocation: Dana Point, CA

A live webcast of the presentations will be available under the “Events & Presentations” tab on the “Investors” page on the Company’s website on the day of the event. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Investor Contact:Sam Martin/Andrew VulisArgot Partners[email protected]

Media Contact:Amanda GalgaySVP, Corporate Communications, Tango Therapeutics [email protected]

Source: Tango Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• KFSH&RC Announced as Strategic Partner for the Saudi American Healthcare Forum 2024
• Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
• TC Energy provides results of Series 7 Shares conversion elections